Flexible Dosing

With the freedom and flexibility of Hizentra, patients can work with their prescriber to create an individualized treatment plan that best fits their lifestyle.

Based on certain criteria, such as body type, dose, and lifestyle, you and your doctor can design a highly individualized treatment plan that fits your needs.

Below are four sample patients with four different treatment plans. Each is able to infuse on a regular schedule and maintain steady state Ig levels, despite their different lifestyles.

Treatment Plan >

Meet Kevin

Second grader who infuses 2x/week

Kevin is a second-grader who enjoys sports and video games. Because of his activity level and low body fat, his parents and prescriber decided on a frequent infusion schedule, resulting in less volume and shorter infusions.

Meet Kevin >

Treatment Plan

May be best for: Steady-state IgG levels, low body fat, and shorter infusion times

Treatment Plan >

Meet Sarah

Busy mother who infuses weekly

Sarah is a busy mom with 2 kids who doesn't have much spare time. Because of her schedule, she likes to keep a weekly routine, infusing Hizentra on her Sunday morning walk.

Meet Sarah >

Treatment Plan

May be best for: Steady-state IgG levels, infusing weekly, and routine schedules

Treatment Plan >

Meet Rose

Grandmother who infuses every 10 days

Rose is a grandmother of six who enjoys baking, knitting and playing cards. Rose prefers to infuse less frequently and finds it easy to remember to infuse on the 5th, 15th and 25th of every month.

Meet Rose >

Treatment Plan

May be best for: Steady-state IgG levels, less frequent infusions, and switching from 10% to 20%

Treatment Plan >

Meet Will

Athletic student who infuses biweekly (every two weeks)

Will is an athletic college student who lives on campus. Because of his privacy concerns with living in the dorm, he prefers to infuse less frequently.

Meet Will >

Treatment Plan

May be best for: Steady-state IgG levels, less frequent infusions, and switching from 10% to 20%

Adapts to Fit Your Changing Lifestyle

As your lifestyle changes over time, the flexibility of Hizentra lets you adapt your dosing schedule to maintain steady Ig levels while meeting your changing needs.

Your Tools for Administering Hizentra

At CSL Behring, we recognize that self-infusion of Ig therapy may be a new experience for healthcare professionals as well as their patients. Next find helpful information and tools on the dosing and administration of Hizentra.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015